Wall Street insiders discuss their stocks to watch in 2026

Investment Themes - Hard assets, including metals and agricultural products, are gaining attention, with soybeans and sugar showing positive movements [2] - Oil prices are nearing $58 per barrel, influenced by geopolitical factors and declining rig counts, suggesting potential upside [3] - The biotech sector, particularly in weight loss and vanity-related treatments, is expected to remain a hot theme [3][12] Sector Focus - Semiconductors and infrastructure plays are highlighted as areas of interest, with companies like Nvidia and emerging cloud computing firms being noted [4] - Robotics and energy sectors, particularly nuclear energy, are also seen as promising investment opportunities [4] Healthcare Sector - The healthcare sector is viewed as a stable investment area, with companies like MEDP (a contract research organization) expected to grow due to their efficient processes [6][7] - Transmetics, focused on improving organ transplant logistics, is identified as a potential high-growth company due to its innovative approach [8][10] Market Outlook - Emerging markets, particularly in China and Latin America, are expected to attract investment as global growth and commodity cycles shift [29][30] - The US stock market is anticipated to face challenges as leadership may shift away from US equities, with a multi-year change in market dynamics expected [28] Commodity Trends - Precious metals, especially gold, are experiencing significant price increases, with forecasts suggesting continued bullish sentiment into next year [58][59] - The oil market is expected to transition from an inventory glut to a potential shortage, driven by global growth and limited low-cost production capacity [34][36] Banking Sector - US banks are recovering but face challenges from non-bank competition and potential credit issues, particularly in commercial lending [39][41] - European banks are outperforming US counterparts, with expectations of a credit cycle beginning in Europe [44][45] Biopharma Industry - The biopharma sector is cautiously optimistic following recent policy resolutions regarding drug pricing, although concerns about FDA efficiency remain [81][83] - M&A activity is anticipated as companies seek to acquire assets in response to patent expirations, with a focus on firms with differentiated drug data [88][90]